In animal models, PPAR agonists can effectively relieve the degree of cholangitis in mice (Nozaki et al., 2013), improve the symptoms of intrahepatic cholestasis in mice and reduce cholestation-related dyslipidemia (Zhang et al., 2020). Here, PPARA is linked to metabolic syndrome.